Cargando…

Intraductal pegylated liposomal doxirubicin may achieve long term protection in HER2/NEU transgenic mice by restricting mammary gland outgrowth

Detalles Bibliográficos
Autores principales:	Sukumar, S, Mori, T, Chun, YS, Zahnow, C, Huso, D
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727099/ http://dx.doi.org/10.1186/1753-6561-3-S5-S27

Ejemplares similares

Developmental and Lactational Exposure to Dieldrin Alters Mammary Tumorigenesis in Her2/neu Transgenic Mice
por: Cameron, Heather L., et al.
Publicado: (2009)

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span
por: Provinciali, Mauro, et al.
Publicado: (2017)

Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice
por: Li, You-Jun, et al.
Publicado: (2015)

A phase 1 study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women awaiting mastectomy
por: Stearns, V, et al.
Publicado: (2009)

Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice
por: Boggio, Katia, et al.
Publicado: (1998)

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice
por: Bandini, Silvio, et al.
Publicado: (2013)

Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice
por: Nanni, Patrizia, et al.
Publicado: (2001)

Dmp1α Inhibits HER2/neu-Induced Mammary Tumorigenesis
por: Fry, Elizabeth A., et al.
Publicado: (2013)

Accelerated Mammary Tumor Onset in a HER2/Neu Mouse Model Exposed to DDT Metabolites Locally Delivered to the Mammary Gland
por: Johnson, Nakpangi A, et al.
Publicado: (2012)

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Croci, Stefania, et al.
Publicado: (2015)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Intraductal Injection for Localized Drug Delivery to the Mouse Mammary Gland
por: Krause, Silva, et al.
Publicado: (2013)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

PEGylated liposomes: immunological responses
por: Mohamed, Marwa, et al.
Publicado: (2019)

CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice
por: Chen, Xuguang, et al.
Publicado: (2016)

Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis
por: Patel, Y, et al.
Publicado: (2018)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

Nutritional combinatorial impact on the gut microbiota and plasma short-chain fatty acids levels in the prevention of mammary cancer in Her2/neu estrogen receptor-negative transgenic mice
por: Sharma, Manvi, et al.
Publicado: (2020)

Ductal Architecture: Corrosion Casting of Canine Mammary Glands Using an Intraductal Approach
por: Kolasinac, Sabina Sibcic, et al.
Publicado: (2023)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Monoclonal Antibody Functionalized, and L-lysine α-Oxidase Loaded PEGylated-Chitosan Nanoparticle for HER2/Neu Targeted Breast Cancer Therapy
por: Saravanakumar, Kandasamy, et al.
Publicado: (2022)

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice
por: Ianzano, Marianna L., et al.
Publicado: (2013)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration
por: Sangrà, Marc, et al.
Publicado: (2017)

Documentation of Complete Response in Metastatic Breast Cancer to Liver and Bone Achieved with Trastuzumab and Pegylated Liposomal Doxorubicin
por: Kobrinsky, Boris, et al.
Publicado: (2008)

The molecular biology of mammary intraepithelial neoplasia outgrowths
por: Namba, L, et al.
Publicado: (2003)

Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model
por: Eralp, Yesim, et al.
Publicado: (2004)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
por: De Giovanni, Carla, et al.
Publicado: (2014)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy
por: Rodrigues, Loreta M, et al.
Publicado: (2012)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Preparation of a PEGylated liposome that co-encapsulates l-arginine and doxorubicin to achieve a synergistic anticancer effect
por: Feng, Haitao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p99simdft18du0mj1snemkfcb8